Developing new drugs is a long, costly and risky process. But a CIFRE thesis, which sparked the creation of an industrial partnership between pharmaceutical group Servier and Inria, has resulted in the development of three tools: a knowledge graph, algorithms, and mathematical models, which could make this work faster, cheaper and safer.
Developing new drugs is a long, costly and risky process. But a CIFRE thesis, which sparked the creation of an industrial partnership between pharmaceutical group Servier and Inria, has resulted in the development of three tools: a knowledge graph, algorithms, and mathematical models, which could make this work faster, cheaper and safer.